470 related articles for article (PubMed ID: 29217776)
1. Melphalan 140 mg/m
Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
[TBL] [Abstract][Full Text] [Related]
2. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
3. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
4. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
[TBL] [Abstract][Full Text] [Related]
5. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
[TBL] [Abstract][Full Text] [Related]
7. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
8. Final outcomes of escalated melphalan 280 mg/m
Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
Mark TM; Reid W; Niesvizky R; Gergis U; Pearse R; Mayer S; Greenberg J; Coleman M; Van Besien K; Shore T
Biol Blood Marrow Transplant; 2013 May; 19(5):831-7. PubMed ID: 23454184
[TBL] [Abstract][Full Text] [Related]
11. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150).
Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS;
Biol Blood Marrow Transplant; 2018 May; 24(5):923-929. PubMed ID: 29339269
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
14. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
15. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
17. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
Lawless S; Sbianchi G; Morris C; Iacobelli S; Bosman P; Blaise D; Reményi P; Byrne JL; Mayer J; Apperley J; Lund J; Kobbe G; Schaap N; Isaksson C; Lenhoff S; Basak G; Touzeau C; Wilson KMO; González Muñiz S; Scheid C; Browne P; Anagnostopoulos A; Rambaldi A; Jantunen E; Kröger N; Schönland S; Yakoub-Agha I; Garderet L
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):686-693. PubMed ID: 34158265
[TBL] [Abstract][Full Text] [Related]
18. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
20. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.
El Fakih R; Fox P; Popat U; Nieto Y; Shah N; Parmar S; Oran B; Ciurea S; Kebriaei P; Hosing C; Ahmed S; Shah J; Orlowski R; Champlin R; Qazilbash M; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):472-6. PubMed ID: 25963284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
